S

ST Pharm Co Ltd
KOSDAQ:237690

Watchlist Manager
ST Pharm Co Ltd
KOSDAQ:237690
Watchlist
Price: 86 100 KRW 0.94% Market Closed
Market Cap: 1.7T KRW
Have any thoughts about
ST Pharm Co Ltd?
Write Note

ST Pharm Co Ltd
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ST Pharm Co Ltd
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
S
ST Pharm Co Ltd
KOSDAQ:237690
Other Liabilities
â‚©43B
CAGR 3-Years
88%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Other Liabilities
â‚©574B
CAGR 3-Years
32%
CAGR 5-Years
32%
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Other Liabilities
â‚©954.1m
CAGR 3-Years
65%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Other Liabilities
â‚©6.8B
CAGR 3-Years
39%
CAGR 5-Years
24%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Other Liabilities
â‚©3.7B
CAGR 3-Years
-11%
CAGR 5-Years
-8%
CAGR 10-Years
4%
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Other Liabilities
â‚©224m
CAGR 3-Years
14%
CAGR 5-Years
-28%
CAGR 10-Years
N/A
No Stocks Found

ST Pharm Co Ltd
Glance View

Market Cap
1.6T KRW
Industry
Life Sciences Tools & Services

Nestled in the bustling metropolis of Seoul, South Korea, ST Pharm Co Ltd. operates as a dynamic player within the global pharmaceutical industry. Established initially to meet the burgeoning demands of the local pharmaceutical market, the company has slowly carved out a niche for itself in the global arena. With a deft focus on the development and manufacture of active pharmaceutical ingredients (APIs), ST Pharm now sets its sights on becoming a central figure in the synthesis of high-value APIs used in therapies including antivirals and oncology treatments. This focus isn't merely driven by opportunity; it's underpinned by a dedicated commitment to cutting-edge research and development. The company has invested heavily in state-of-the-art facilities and nurtures a team of seasoned scientists who remain at the forefront of innovation. ST Pharm makes its revenue by mastering the art of efficient and reliable API production. By optimizing their production processes, they can offer a competitive edge—delivering high-quality products at scale. The company isn't solely interested in the immediate gains of API manufacture; it also sees potential in providing customized solutions to its diverse clientele, which spans multinational pharmaceutical giants to nimble biotech startups. Partnerships and collaborations have become crucial strategies for ST Pharm, facilitating an exchange of innovation and expertise that keeps them relevant and forward-thinking. In this regard, their business model elegantly balances between standardized API production and bespoke chemical solutions, ensuring a steady revenue stream while opening doors to future advancements in pharmaceutical science.

Intrinsic Value
103 228.82 KRW
Undervaluation 17%
Intrinsic Value
Price
S

See Also

What is ST Pharm Co Ltd's Other Liabilities?
Other Liabilities
43B KRW

Based on the financial report for Sep 30, 2024, ST Pharm Co Ltd's Other Liabilities amounts to 43B KRW.

What is ST Pharm Co Ltd's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
49%

Over the last year, the Other Liabilities growth was 34%. The average annual Other Liabilities growth rates for ST Pharm Co Ltd have been 88% over the past three years , 49% over the past five years .

Back to Top